Overview
Phio Pharmaceuticals
Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on our self-delivering RNAi
(“INTASYL™”) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression
of the immune system through our proprietary INTASYL™ platform with utility in immune cells and/or the tumor micro-environment. Our
goal is to develop powerful INTASYL™ therapeutic compounds that can weaponize immune effector cells to overcome tumor immune
escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities.
Our development efforts are based on our
broadly patented INTASYL™ technology platform. Our INTASYL™ compounds do not require a delivery vehicle to penetrate
into tissues and cells and are designed to “silence” or down-regulate, the expression of a specific gene which is over-expressed
in cancer. We believe that our INTASYL™ platform uniquely positions the Company in the field of immuno-oncology because of
this and the following reasons:
|
·
|
Efficient uptake of INTASYL™ to immune cells obviating the need for facilitated delivery (mechanical or formulation);
|
|
·
|
Can target multiple genes (i.e. multiple immunosuppression pathways) in a single therapeutic entity;
|
|
·
|
Gene silencing by INTASYL™ has been shown to have a sustained, or long-term, effect in vivo;
|
|
·
|
Favorable clinical safety profile of INTASYL™ with local administration; and
|
|
·
|
Can be readily manufactured under current good manufacturing practices.
|
Our Development Pipeline
The table below sets forth the Company’s
stage of development for its programs and product candidates:
The self-delivering
nature of our compounds makes INTASYL™ ideally suited for use with
adoptive cell transfer (“ACT”) treatments and direct therapeutic use. ACT consists of the infusion of immune
cells with antitumor properties. These cells can be derived from unmodified (i.e. naturally occurring) immune cells, immune cells
isolated from resected tumors, or genetically engineered immune cells recognizing tumor neoantigen/neoepitope cells.
Currently, ACT
therapies for the treatment of solid tumors face several hurdles. Multiple inhibitory mechanisms restrain immune cells used in
ACT from effectively eradicating tumors, including immune checkpoints, reduced cell fitness and cell persistence. Furthermore,
the immunosuppressive tumor micro-environment (the “TME”) can pose a formidable barrier to immune cell infiltration
and function.
Phio has developed
a product platform based on our INTASYL™ technology that allows easy,
precise, rapid, and selective non-genetically modified programming of ACT cells (ex vivo, during manufacturing) and of the
TME (in vivo, by local application), resulting in improved immunotherapy.
Adoptive Cell Transfer
ACT includes a number of different types
of immunotherapy treatments. These treatments use immune cells, that are grown in a lab to large numbers, followed by administering
them to the body to fight the cancer cells. Sometimes, immune cells that naturally recognize a tumor are used, while other times
immune cells are modified or “engineered” to make them recognize and kill the cancer cells. There are several types
of ACT, including: a.) non-engineered cell therapy in which immune cells are grown from the patient’s tumor or blood, such
as tumor infiltrating lymphocytes (“TILs”), or from donor blood or tissue such as natural killer (“NK”)
cells, dendritic cells (“DC”) and macrophages, and b.) engineered immune cells that are genetically modified
to recognize specific tumor proteins and to remain in an activated state (such as T cell receptor technology (“TCRs”),
chimeric antigen receptor (“CAR”) T cells, or CAR-NK cells).
In
ACT, immune cells are isolated from patients, donors or retrieved from allogeneic immune cell banks. The immune cells are then
expanded and modified before being returned and used to treat the patient. We believe our INTASYL™ compounds are
ideally suited to be used in combination with ACT, in order to make these immune cells more effective.
Our approach
to immunotherapy builds on well-established methodologies of ACT and involves the treatment of immune cells with our INTASYL™ compounds
while they are grown in the lab and before administering them to the patient. Because our INTASYL™ compounds
do not require a delivery vehicle to penetrate into the cells, we are able to enhance the function of these cells (for
example, by inhibiting the expression of immune checkpoint genes) by merely adding our INTASYL™ compounds
during the expansion process and without the need for genetic engineering. After enhancing these cells ex vivo, they
are returned to the patient for treatment.
Our method introduces an important
step in the ex vivo processing of immune cells. This step uses our INTASYL™ technology to reduce or eliminate
the expression of genes that make the immune cells less effective. For example, with our INTASYL™ compounds, we can
reduce the expression of immunosuppressive receptors or proteins by the therapeutic immune cells, potentially enabling them
to overcome tumor resistance mechanisms and thus improving their ability to destroy the tumor cells. In
various types of immune cells tested to date, INTASYL™ treatment results in potent silencing while maintaining
close to 100% transfection efficiency and nearly full cell viability.
One of the main
issues with ACT is that the cells are very susceptible to the cancer signals that turn down the immune response and continuous
activation of these cells causes them to become exhausted. These factors, among others, may reduce their efficacy and lifespan.
A technology that can reprogram the immune cells used in ACT, such as with INTASYL™ technology, is of key interest now in
the current immuno-oncology world. In comparison to other technologies available, reprogramming cells with INTASYL™ does
not require genetic engineering, its use is not limited to specific cell types and can be easily integrated with cell manufacturing
approaches.
We currently have two product candidates
that are being developed for use in ACT, PH-762 and PH-804. PH-762, our most advanced program and lead pipeline compound, targets
the checkpoint protein PD-1, a checkpoint protein on immune cells. PD-1 normally acts as a type of “off switch” that
helps keep the T cells from attacking other cells in the body. T cells are immune cells that protect the body from cancer cells
and are important for the activation of immune cells to fight infection. Our second pipeline compound, PH-804, targets the suppressive
immune receptor TIGIT, which is a checkpoint protein present on T cells and NK cells.
Data developed in-house and with our collaborators,
which include both leading academic centers and corporate institutions, has shown that PH-762 can elicit PD-1 checkpoint blockade
by silencing PD-1 receptor expression resulting in enhanced T cell activation and tumor cytotoxicity. We have also shown with studies
completed with our collaborators that PH-804 can silence the expression of TIGIT in NK cells and T cells, overcoming their exhaustion
and thereby becoming “weaponized.”
Recent data shown by the Company as well
as with our collaborators, Iovance Biotherapeutics, Inc. and the Karolinska Institutet, at the 2019 Society for Immunotherapy
of Cancer annual meeting further supports the application of INTASYL™ technology in immunotherapy of cancer. PH-762 has
shown to silence the expression of checkpoint molecule PD-1 in target human T cells in a potent and durable manner suitable for
both ACT and intra-tumoral injection, and increases function of patient derived TILs for ACT. The application of INTASYL™
compounds to novel immuno-oncology targets was shown by the silencing of BRD4, a regulator of gene expression impacting cell differentiation
and function, by a BRD4 targeting INTASYL™ compound in human T cells during expansion for ACT, which has the potential to
confer superior anti-tumor activity.
We expect that
PH-762 can be ready to enter into the clinic with a partner in ACT therapy in the second half of 2020 and we are developing PH-804
with the aim to enter the clinic with a partner in ACT in 2021.
Tumor Micro-Environment
The TME is the environment that surrounds
and feeds a tumor, including normal cells, blood vessels, immune cells and the extracellular matrix. A tumor can change the microenvironment
and the microenvironment can affect how a tumor grows and spreads and can create an immunosuppressive microenvironment that inhibits
the immune system’s natural ability to recognize and destroy tumor cells. This attracts immunosuppressive cells, induces
and activates immune checkpoint expression and excludes and exhausts T cells. Reprogramming different components of the TME may
overcome its resistance to immunotherapy.
Such reprogramming of the TME by INTASYL™
compounds through direct local administration into the tumor, could potentially become an important form of (neo)adjuvant therapy.
We believe that this will also show that our contributions with our INTASYL™ compounds
in immuno-oncology are not limited to use with a cell therapy platform. Additionally, the Company has shown in a clinical setting
that its INTASYL™ compounds are safe and well-tolerated following
local administration.
Our INTASYL™ compounds being developed
for use in ACT, are also being developed for use directly towards the TME, including PH-762 and PH-804. We are also working on
other relevant compounds for TME targets, such as PH-790, an INTASYL™ compound targeting PD-L1. PD-L1 is a protein that keeps
immune cells from attacking nonharmful cells in the body. If cancer cells have large amounts of PD-L1, this “tricks”
the immune system into not recognizing and attacking the tumor. Our approach with PH-790 is to block the PD-L1 protein, which may
prevent cancer cells from inactivating T cells and attack the cancer.
Our collaborative research agreement with
Gustave Roussy, a leading comprehensive cancer center in France, concentrates on determining the feasibility of our INTASYL™ platform
to target the TME via intra-tumoral injection. An in vivo study completed with Gustave Roussy demonstrated that
an INTASYL™ compound delivered via intra-tumoral injection showed
silencing of gene expression with our INTASYL™ compounds with greater
than 90% reduction of the target gene expression in a mouse model of melanoma.
Recent in vivo studies
performed by the Company showed that intra-tumoral injections of a mouse version of PH-804 reduced the tumor growth in colorectal
carcinoma tumor bearing mice, which was shown to be correlated with the silencing of TIGIT messenger RNA (“mRNA”)
expression and an increase in cytotoxic effector T cells in the TME.
The Company expects to move PH-762 for intra-tumoral
injection into the clinical development stage in 2021.
Our INTASYL™ Platform
Diseases are often related to the wrong
protein being made, excessive amounts of a specific protein being made, or the correct protein being made but at the wrong location
or time. Overall, RNA is involved in the synthesis, regulation and processing of proteins. RNA interference (“RNAi’)
is a biological process in which RNA molecules inhibit gene expression or translation into proteins by preventing certain RNA from
being read. RNAi offers a novel approach to the drug development process because RNAi compounds can potentially be designed to
target any one of the thousands of human genes, many of which are “undruggable” by other modalities. Supported by numerous
gene-silencing reports and our own research, we believe that this sequence information can be used to design RNAi compounds to
interfere with the expression of almost any specific gene.
The first design of RNAi compounds to be
pursued for the development of human therapeutics were short, double-stranded RNAs that included limited modifications, known as
small-interfering RNA (“siRNA”). Since the initial discovery of RNAi, drug delivery has been the primary challenge
in developing RNAi-based therapeutics. One conventional solution to the delivery problem involves encapsulation of siRNA into a
lipid-based particle, such as a liposome, to improve circulation time and cellular uptake. We have developed an alternative approach
where delivery and drug-like properties are built directly into the RNAi compound itself. These novel compounds are termed self-delivering
RNAi compounds, or INTASYL™.
Our INTASYL™ compounds are hybrid
oligonucleotide compounds that the Company believes combines the beneficial properties of both conventional RNAi and antisense
technologies. Traditional, single-stranded antisense compounds have favorable tissue distribution and cellular uptake properties.
However, they do not have the intracellular potency that is a hallmark of double-stranded RNAi compounds. Conversely, the duplex
structure and hydrophilic character of traditional RNAi compounds results in poor tissue distribution and cellular uptake. In an
attempt to combine the best properties of both technologies, INTASYL™ compounds have a single-stranded phosphorothioate region,
a short duplex region, and contain a variety of nuclease-stabilizing and lipophilic chemical modifications. The combination of
these features allows INTASYL™ compounds to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular
activity.
We believe that our next generation INTASYL™
compounds offer significant advantages over siRNAs used by other companies developing RNAi therapeutics, which are highlighted
by the following characteristics:
|
·
|
Efficient cellular uptake in the absence of a delivery vehicle;
|
|
·
|
More resistant to nuclease degradation than unmodified oligonucleotides;
|
|
·
|
Ability to suppress long non-coding RNAs, both in cytoplasm and the nucleus;
|
|
·
|
Potentially more specific for the target gene; and
|
|
·
|
Reduced immune side effects compared to classic siRNA.
|
The route by which our INTASYL™ compounds
are brought into contact with the body depends on the intended organ or tissue to be treated. Delivery routes can be simplified
into two major categories: (1) local, or when a drug is delivered directly to the tissue of interest, and (2) systemic,
when a drug accesses the tissue of interest through the circulatory system. The key to therapeutic success with RNAi lies in delivering
intact RNAi compounds to the target tissue and the interior of the target cells. To accomplish this, our chemically synthesized
INTASYL™ compounds are optimized for stability and efficacy and have unique properties that improve tissue and cell uptake.
Intellectual Property
We protect our proprietary information by
means of United States and foreign patents, trademarks and copyrights. In addition, we rely upon trade secret protection and contractual
arrangements to protect certain of our proprietary information and products. We have pending patent applications that relate to
potential drug targets, compounds we are developing to modulate those targets, methods of making or using those compounds and proprietary
elements of our drug discovery platform.
Much of our technology and many of our processes
depend upon the knowledge, experience and skills of key scientific and technical personnel. To protect our rights to our proprietary
know-how and technology, we require all employees, as well as our consultants and advisors when feasible, to enter into confidentiality
agreements that require disclosure and assignment to us of ideas, developments, discoveries and inventions made by these employees,
consultants and advisors in the course of their service to us, and we vigorously defend that position with partners, as well as
with employees who leave the Company.
We have also obtained rights to various
patents and patent applications under licenses with third parties, which require us to pay royalties, milestone payments, or both.
The degree of patent protection for biotechnology products and processes, including ours, remains uncertain, both in the United
States and in other important markets, because the scope of protection depends on decisions of patent offices, courts and lawmakers
in these countries. There is no certainty that our existing patents or others, if obtained, will afford us substantial protection
or commercial benefit. Similarly, there is no assurance that our pending patent applications or patent applications licensed from
third parties will ultimately be granted as patents or that those patents that have been issued or are issued in the future will
stand if they are challenged in court. We assess our license agreements on an ongoing basis and may from time to time terminate
licenses to technology that we do not intend to employ in our technology platforms, or in our product discovery or development
activities.
Patents and Patent Applications
We are actively seeking protection for our
intellectual property and are prosecuting a number of patents and pending patent applications covering our compounds and technologies.
A combined summary of these patents and patent applications is set forth below in the following table:
|
|
|
Pending
Applications
|
|
|
|
Issued
Patents
|
|
United States
|
|
|
24
|
|
|
|
41
|
|
Canada
|
|
|
10
|
|
|
|
4
|
|
Europe
|
|
|
14
|
|
|
|
45
|
|
Japan
|
|
|
12
|
|
|
|
13
|
|
Other Markets
|
|
|
16
|
|
|
|
9
|
|
Our portfolio includes 112 issued patents,
45 of which cover our INTASYL™ platform. There are 16 patent families broadly covering both the composition and methods of
use of our self-delivering platform technology and uses of our INTASYL™ compounds targeting immune checkpoint, cellular differentiation
and metabolism targets for ex vivo cell-based cancer immunotherapies. These patents are scheduled to expire between 2029
and 2038. Furthermore, there are 71 patent applications, encompassing what we believe to be important new RNAi compounds and their
use as therapeutics, chemical modifications of RNAi compounds that improve the compounds’ suitability for therapeutic uses
(including delivery) and compounds directed to specific targets (i.e., that address specific disease states). The patents
and any patents that may issue from these pending patent applications will, if issued, be set to expire between 2022 and 2038,
not including any patent term extensions that may be afforded under the Federal Food, Drug, and Cosmetic Act (“FFDCA”)
(and the equivalent provisions in foreign jurisdictions) for any delays incurred during the regulatory approval process relating
to human drug products (or processes for making or using human drug products).
Option
and License Agreements
Medigene
AG and the Helmholtz Zentrum München. On
March 6, 2020, we entered into a Collaboration and Option Agreement (the “Collaboration Agreement”) with Medigene
AG and the Helmholtz Zentrum München (“HMGU”). The Collaboration Agreement
expands upon the Company’s outstanding research agreement with HMGU to design and develop novel candidates for the use of
INTASYL™ compounds in ACT to enhance immune cell function. Under the Collaboration Agreement, Medigene will contribute expertise
regarding clinical development, as well as proprietary research material, and has an option to an exclusive license for the clinical
and/or commercial exploitation of the potential immune cell enhancers against certain fee payments.
We have secured exclusive and non-exclusive
rights to develop therapeutics by licensing key RNAi technologies and patent rights from third parties. These rights relate to
chemistry and configuration of compounds, delivery technologies of compounds to cells and therapeutic targets. As we continue to
develop our own proprietary compounds, we continue to evaluate both our in-licensed portfolio as well as the field for new technologies
that could be in-licensed to further enhance our intellectual property portfolio and unique position in the RNAi and immuno-oncology
space.
Advirna LLC. In September 2011, we
entered into an agreement with Advirna, LLC (“Advirna”) pursuant to which Advirna assigned to us its existing
patent and technology rights related to the INTASYL™ technology in exchange for our agreement to issue to Advirna common
stock equal to 5% of the Company’s fully-diluted shares, pay an annual maintenance fee of $100,000 and pay a one-time milestone
payment of $350,000 upon the issuance of the first patent with valid claims covering the assigned technology. The common shares
of the Company were issued to Advirna in 2012 upon the completion of the spin-out from our former parent company and the one-time
milestone payment was paid in 2014. Additionally, we will be required to pay a 1% royalty to Advirna on any license revenue received
by us with respect to future licensing of the assigned Advirna patent and technology rights. To date, royalties owed to Advirna
under the agreement have been minimal. We also granted back to Advirna a license under the assigned patent and technology rights
for fields of use outside human therapeutics and diagnostics.
Our rights under the Advirna agreement will
expire upon the later of: (i) the expiration of the last-to-expire of the “patent rights” (as defined therein)
or (ii) the abandonment of the last-to-be abandoned of such patents, unless earlier terminated in accordance with the provisions
of the agreement.
We may terminate the Advirna agreement at
any time upon 90 days’ written notice to Advirna, and Advirna may terminate the agreement upon 90 days’ prior written
notice in the event that we cease using commercially reasonable efforts to research, develop, license or otherwise commercialize
the patent rights or “royalty-bearing products” (as defined therein), provided that we may refute such claim within
such 90-day period by showing budgeted expenditures for the research, development, licensing or other commercialization consistent
with other technologies of similar stage of development and commercial potential as the patent rights or royalty-bearing products.
Further, either party at any time may provide to the other party written notice of a material breach of the agreement. If the other
party fails to cure the identified breach within 90 days after the date of the notice, the aggrieved party may terminate the agreement
by written notice to the party in breach.
Legacy Dermatology and Ophthalmology Programs
In January 2018, the Company announced
that it was exploring strategic alternatives, including a potential sale or out-license, with respect to the Company’s legacy
dermatology and ophthalmology programs following the Company’s change in strategic direction to focus solely on immuno-oncology.
Due to resource constraints, the Company has significantly reduced its efforts to out-license or sell these programs and does
not expect to provide further updates on these assets going forward.
Research and Development
Our research and development expense primarily
consists of compensation and benefits for research and development personnel, facility-related expenses, supplies, external services,
costs to acquire technology licenses, expenses associated with preclinical and clinical development activities and other operating
costs.
Total research and development expense for
the years ended December 31, 2019 and 2018 was $4,300,000 and $4,326,000, respectively.
Competition
The biotechnology and pharmaceutical industries,
including the immuno-oncology field, are a constantly evolving landscape with rapidly advancing technologies and significant competition.
There are a number of competitors in the immuno-oncology field including large and small pharmaceutical and biotechnology companies,
academic institutions, government agencies and other private and public research organizations.
A variety of cell-based autologous and
allogeneic approaches are being researched and developed, including but not limited to: CAR-T cells, TCR-T cells, Gamma Delta
T cells, CAR-NK cells, NK cells, NKT cells and cytotoxic T cells. We believe that competitors in this field include, but are not
limited to: Adicet Bio, Inc., Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics plc, Baylor College
of Medicine, Bellicum Pharmaceuticals, Inc., bluebird bio, Inc., Celyad S.A., Celgene Corporation, Cell Medica Ltd., Cellectis
S.A., Celularity, Inc., CiMaas B.V., CRISPR Therapeutics AG, Fate Therapeutics, Inc., Formula Therapeutics, Inc., Fortress Biotech,
Inc., GAIA Biomedicine Inc., Glycostem Therapeutics BV, Immatics Biotechnologies GmbH, Iovance Biotherapeutics, Inc., Intrexon
Corporation, Janssen Biotech, Inc., Kite Pharma, Inc.(a Gilead company), Medigene AG, Mustang Bio, Inc., NantKwest, Inc., BioNTech
NE, Novartis International AG, Precigen, Inc., Refuge Biotechnologies, Inc., Sorrento Therapeutics, Inc., Tactiva Therapeutics,
Inc., TC BioPharm Limited and Ziopharm Oncology, Inc.
A number of technological approaches to
modulating gene expression in the field of immuno-oncology have been identified and are being researched and developed, including
but not limited to: antisense oligodeoxynucleotides, RNAi, zinc-finger nucleases, transcription activator-like effector nucleases,
mRNA, and genetic engineering techniques such as clustered regularly interspaced short palindromic repeats, or CRISPR, and various
others. We believe that competitors in this field include, but are not limited to: BioNTech NE, Cellectis S.A., CRISPR Therapeutics
AG, Dicerna Pharmaceuticals, Inc., Editas Medicine, Inc., eTheRna immunotherapies NV, Horizon Discovery Group plc, Intellia Therapeutics,
Inc., Kymera Therapeutics Inc., miRagen Therapeutics, Inc., Moderna, Inc., Noxxon Pharma N.V., Obsidian Therapeutics, Inc., OliPass
Corporation, OncoSec Medical Incorporated, Mateon Therapeutics, Inc., PTC Therapeutics, Inc., Sangamo Therapeutics, Inc., Sirnaomics,
Inc., Stemirna Therapeutics Co., Ltd. and Takara Bio Inc.
Government Regulation
The United States and many other countries
extensively regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion,
export, marketing and distribution of drugs and biologic products. The U.S. Food and Drug Administration (“FDA”)
regulates pharmaceutical and biologic products under the FFDCA, the Public Health Service Act and other federal statutes and regulations.
To obtain approval of our future product
candidates from the FDA, we must, among other requirements, submit data supporting safety and efficacy for the intended indication
as well as detailed information on the manufacture and composition of the product candidate. In most cases, this will require extensive
laboratory tests and preclinical and clinical trials. The collection of these data, as well as the preparation of applications
for review by the FDA involve significant time and expense. The FDA also may require post-marketing testing to monitor the safety
and efficacy of approved products or place conditions on any approvals that could restrict the therapeutic claims and commercial
applications of these products. Regulatory authorities may withdraw product approvals if we fail to comply with regulatory standards
or if we encounter problems at any time following initial marketing of our products.
The first stage of the FDA approval process
for a new biologic or drug involves completion of preclinical studies and the submission of the results of these studies to the
FDA. These data, together with proposed clinical protocols, manufacturing information, analytical data and other information submitted
to the FDA in an investigational new drug (“IND”) application, must become effective before human clinical trials
may commence. Preclinical studies generally involve FDA regulated laboratory evaluation of product characteristics and animal studies
to assess the efficacy and safety of the product candidate.
After the IND becomes effective, a company
may commence human clinical trials. These are typically conducted in three sequential phases, but the phases may overlap. Phase
1 trials consist of testing the product candidate in a small number of patients or healthy volunteers, primarily for safety at
one or more doses. Phase 2 trials, in addition to safety, evaluate the efficacy of the product candidate in a patient population
somewhat larger than Phase 1 trials. Phase 3 trials typically involve additional testing for safety and clinical efficacy in an
expanded population at multiple test sites. A company must submit to the FDA a clinical protocol, accompanied by the approval of
the Institutional Review Board (“IRB”) at the institutions participating in the trials, prior to commencement
of each clinical trial.
To obtain FDA marketing authorization, a
company must submit to the FDA the results of the preclinical and clinical testing, together with, among other things, detailed
information on the manufacture and composition of the product candidate, in the form of a new drug application (“NDA”),
or, in the case of a biologic, a biologics license application (“BLA”).
The amount of time taken by the FDA for
approval of an NDA or BLA will depend upon a number of factors, including whether the product candidate has received priority review,
the quality of the submission and studies presented, the potential contribution that the compound will make in improving the treatment
of the disease in question and the workload at the FDA.
The FDA may, in some cases, confer upon
an investigational product the status of a fast track product. A fast track product is defined as a new drug or biologic intended
for the treatment of a serious or life-threatening condition that demonstrates the potential to address unmet medical needs for
this condition. The FDA can base approval of an NDA or BLA for a fast track product on an effect on a surrogate endpoint, or on
another endpoint that is reasonably likely to predict clinical benefit. If a preliminary review of clinical data suggests that
a fast track product may be effective, the FDA may initiate review of entire sections of a marketing application for a fast track
product before the sponsor completes the application.
We anticipate that our products will be
manufactured by our strategic partners, licensees or other third parties. Before approving an NDA or BLA, the FDA will inspect
the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities are in
compliance with the FDA’s current good manufacturing practice regulations (“cGMP”), which are regulations
that govern the manufacture, holding and distribution of a product. Manufacturers of biologics also must comply with the FDA’s
general biological product standards. Our manufacturers also will be subject to regulation under the Occupational Safety and Health
Act, the Nuclear Energy and Radiation Control Act, the Toxic Substance Control Act and the Resource Conservation and Recovery Act
and other applicable environmental statutes. Following approval, the FDA periodically inspects drug and biologic manufacturing
facilities to ensure continued compliance with the cGMP. Our manufacturers will have to continue to comply with those requirements.
Failure to comply with these requirements subjects the manufacturer to possible legal or regulatory action, such as suspension
of manufacturing or recall or seizure of product. Adverse patient experiences with the product must be reported to the FDA and
could result in the imposition of marketing restrictions through labeling changes or market removal. Product approvals may be withdrawn
if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur
following approval.
The labeling, advertising, promotion, marketing
and distribution of a drug or biologic product also must be in compliance with FDA and Federal Trade Commission requirements which
include, among others, standards and regulations for off-label promotion, industry sponsored scientific and educational activities,
promotional activities involving the internet, and direct-to-consumer advertising. We also will be subject to a variety of federal,
state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and
radioactive and biological materials. In addition, we will be subject to various laws and regulations governing laboratory practices
and the experimental use of animals. In each of these areas, as above, the FDA has broad regulatory and enforcement powers, including
the ability to levy fines and civil penalties, suspend or delay issuance of product approvals, seize or recall products and deny
or withdraw approvals.
We will also be subject to a variety of
regulations governing clinical trials and sales of our products outside the United States. Whether or not FDA approval has been
obtained, approval of a product candidate by the comparable regulatory authorities of foreign countries and regions must be obtained
prior to the commencement of marketing the product in those countries. The approval process varies from one regulatory authority
to another and the time may be longer or shorter than that required for FDA approval. In the European Union, Canada and Australia,
regulatory requirements and approval processes are similar, in principle, to those in the United States.
Environmental Compliance
Our research and development activities
involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals and various radioactive
compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of
these materials and specific waste products. We are also subject to numerous environmental, health and workplace safety laws and
regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous
materials. The cost of compliance with these laws and regulations could be significant and may adversely affect capital expenditures
to the extent we are required to procure expensive capital equipment to meet regulatory requirements.
Employees
As of March 20, 2020, we had eleven
full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement nor
have we experienced any work stoppages.
Corporate Information
On January 10, 2020, the Board of Directors
of the Company approved a 1-for-55 reverse stock split of the Company’s outstanding common stock, which was effected on January 15,
2020. All share and per share amounts have been adjusted to give effect to the reverse stock split.
We were incorporated in the state of Delaware
in 2011 as RXi Pharmaceuticals Corporation. On November 19, 2018, the Company changed its name to Phio Pharmaceuticals Corp., to
reflect its transition from a platform company to one that is fully committed to developing groundbreaking immuno-oncology therapeutics.
Our executive offices are located at 257 Simarano Drive, Suite 101, Marlborough, MA 01752, and our telephone number is (508) 767-3861.
The Company’s website address is http://www.phiopharma.com.
We make available on our website, free of charge, copies of our annual reports on Form 10-K, our quarterly reports on Form 10-Q
and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d)
of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) as soon as reasonably practicable after
these reports are filed electronically with, or otherwise furnished to, the Securities and Exchange Commission (the “SEC”).
We also make available on our website the charters of our audit committee, compensation committee and nominating and corporate
governance committee, as well as our corporate code of ethics and conduct.
You may read and copy any materials the
Company files with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains
reports, proxy and information statements, and other information regarding Phio and other issuers that file electronically with
the SEC. The SEC’s website address is http://www.sec.gov. The contents of these websites are not incorporated by reference
into this report and should not be considered to be part of this report.
Risks Relating to Our Business and Industry
Our business and operations may be
materially and adversely affected by the recent coronavirus outbreak.
In December 2019, a novel strain of coronavirus
was reported to have surfaced in Wuhan, China and has since spread to other parts of the world, including the United States and
Europe. In March 2020, the World Health Organization declared the outbreak a pandemic. The coronavirus pandemic is affecting the
United States and global economies. If the outbreak continues to spread, it may affect the Company’s operations and those
of third parties on which the Company relies, including causing disruptions in the supply of the Company’s product candidates
and the conduct of current and planned preclinical and clinical studies. We may need to limit operations or implement limitations,
and may experience limitations in employee resources. There are risks that it may be more difficult to contain if the outbreak
reaches a larger population or broader geography, in which case the risks described herein could be elevated significantly. The
extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be
predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the
coronavirus or treat its impact, among others.
Additionally, while the potential economic
impact brought by, and the duration of, the coronavirus pandemic is difficult to assess or predict, the impact of the coronavirus
on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s
short-term and long-term liquidity and the Company’s ability to complete its preclinical studies on a timely basis, or at
all. For instance, our preclinical and clinical may be temporarily delayed or paused, and the operations of our contracted third
parties may be significantly delayed as well. The ultimate impact of coronavirus is highly uncertain and subject to change. The
Company does not yet know the full extent of potential delays or impacts on its business, financing or preclinical and clinical
trial activities or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity,
capital resources, operations and business and those of the third parties on which we rely.
Our product
candidates are in an early stage of development and may fail or experience significant delays or may never advance to the clinic,
which may materially and adversely impact our business.
All of our pipeline programs are in preclinical
development and our future success heavily depends on the successful development of our INTASYL™ product candidates, which
may never occur. These product candidates could be delayed, not advance into the clinic or unexpectedly fail at any stage of development.
Before we can commence clinical trials for a product candidate, we must conduct extensive preclinical and other non-clinical tests
in order to support an IND application, including IND-enabling good laboratory practice (“GLP”) toxicology studies,
in the United States or their equivalents with regulatory authorities in other jurisdictions. Preclinical studies and clinical
trials are expensive, difficult to design and can take many years. There is no assurance that we will be able to successfully develop
our product candidates, and we may focus our efforts and resources on product candidates that may prove to be unsuccessful.
We cannot be certain of the outcome of
preclinical testing and clinical studies and results from these studies may not predict the results that will be obtained in later
phase trials of our product candidates. Even if we are able to complete our preclinical studies and planned clinical trials in
line with our projected timelines, results from such studies and trials may be not replicated in subsequent preclinical studies
or clinical trial results. Additionally, such studies may be delayed due to events beyond our control including as a result of
natural disasters, epidemics or pandemic outbreaks such as the novel coronavirus. Further, the FDA, or equivalent regulatory authority,
may not accept the results of our preclinical studies or proposed clinical study designs and may require the Company to complete
additional preclinical studies or impose stricter approval conditions than we expect. As a result, we cannot guarantee that we
will be able to submit INDs, or similar applications, within our projected timelines, if at all, or that the FDA, or similar regulatory
authorities, will allow us to commence clinical trials.
We are dependent on collaboration
partners for the successful development of our adoptive cell therapy product candidates.
We are not a cell company and expect to
depend on third-party collaborators to support the clinical development of our ACT product candidates. We have entered into research
agreements with our academic and industry collaborators, each of which is terminable by the relevant party at any time, subject
to applicable notice periods. We may not be successful in negotiating agreements with these collaborators to continue the development
and commercialization of our ACT product candidates through collaborations such as joint development or licensing agreements. Our
ability to successfully negotiate such agreements will depend on, among other things, potential partners’ evaluation of the
superiority of our technology over competing technologies, the quality of preclinical data that we have generated, the perceived
risks specific to developing our product candidates and our partners’ own strategic and corporate objectives. If we fail
to negotiate these agreements, we may not be able commence clinical trials with our ACT product candidates or we may be required
to obtain licenses from third-party cell companies and our business, financial condition, results of operations and prospects could
be materially and adversely affected.
We rely upon third-party relationships
to conduct preclinical studies, and any future clinical trials, for our product candidates and may not be able to establish or
maintain the third-party relationships that are necessary to support their development.
We depend upon third-party contract research
organizations (“CROs”), medical institutions, clinical investigators, consultants and other third parties to
support our preclinical research efforts such as through managing and conducting research studies, formulating our product candidates
and manufacturing our product candidates and expect to rely on the same for our future clinical trials. Because we rely on these
third parties, we cannot necessarily control the timing, quality of work or amount of resources that our contract partners will
devote to these activities and we cannot guarantee that these parties will fulfill their obligations to us under these arrangements.
Furthermore, we compete with many other companies for the resources of these third parties, some of which may be our competitors,
and may detract from our programs. Additionally, our contracted CROs and other third parties we rely upon may be impacted by the
coronavirus outbreak, resulting in delays or interruptions, If these third parties do not successfully carry out their responsibilities,
as well as within a timely fashion, our preclinical and clinical development may be delayed, unsuccessful or otherwise adversely
affected.
We cannot guarantee that we will be able
to successfully negotiate agreements with or maintain relationships with these third parties on favorable terms, if at all. If
we are unable to obtain or maintain these agreements, we may not be able to develop, formulate, manufacture, obtain regulatory
approval(s) or commercialize our product candidates. The third parties whom we rely on generally may terminate their agreements
with us at any time, subject to applicable notice periods, and we may not be able to readily terminate any such agreements with
contract partners even if such partners do not fulfill their obligations to us. If we have to enter into alternative arrangements
it may delay or adversely affect the development of our product candidates and our business operations.
We rely upon third parties for the
manufacture of our product candidates.
We rely on third party suppliers and manufacturers
to provide us with the materials and services to manufacture our INTASYL™ compounds and product candidates for certain of
our preclinical research and expect that we will rely on them for our future clinical trials. While we do have in-house expertise
and capacity to manufacture our INTASYL™ compounds, we do not own or lease manufacturing facilities or have our own supply
source for the required materials. Accordingly, we will be dependent upon third party suppliers and our contract manufacturers
to obtain supplies, and we will need to either develop, contract for, or otherwise arrange for the necessary manufacturers for
these supplies. If for any reason we are unable to obtain the supplies for our INTASYL™ compounds from our current manufacturer,
we would have to seek to obtain it from another major manufacturer. There is no assurance that we will be able to timely secure
needed supply arrangements on satisfactory terms, or at all.
Although we have used multiple contract
manufacturers, we currently contract with only one manufacturer for the supply of our clinical product candidates. There is no
assurance that our supply of our clinical drug product will not be limited, interrupted, of satisfactory quality or be available
at acceptable prices. If for any reason we are unable to obtain the clinical supply of our product candidates from our current
manufacturer, we would have to seek to contract with another major manufacturer. While we believe that we currently have sufficient
supply of our PH-762 product candidate for our planned preclinical and clinical studies, some of our other product candidates
or the materials contained therein, may come from facilities in areas impacted by the coronavirus, which may result in delays
or shortages due to ongoing efforts to address the outbreak. Our failure to secure these arrangements as needed could have a material
adverse effect on our ability to complete the development of our clinical product candidates or, if we obtain regulatory approval,
to commercialize them.
The FDA, or equivalent regulatory authority,
governs the manufacturing process for product candidates and will inspect the facilities at which the product manufactured. Approval
of the product will not occur unless the manufacturing facilities are in compliance with the FDA’s cGMP regulations, or equivalent
foreign authority. If our suppliers or manufacturers do not comply with the FDA or foreign regulations for our product candidates,
we may experience delays in timing or supply, be forced to manufacture our product candidates ourselves or seek to enter contract
with another supplier or manufacturer. If we are required to switch suppliers or manufacturers, we will be required to verify that
the new supplier or manufacturer maintains facilities and processes in line with cGMP regulations, which may result in delays,
additional expenses, and may have a material adverse effect on our ability to complete the development of our product candidates.
Natural disasters, epidemic or pandemic
disease outbreaks, trade wars, political unrest or other events could disrupt our business or operations or those of our development
partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future.
A wide variety of events beyond our control,
including natural disasters, epidemic or pandemic disease outbreaks (such as the recent novel coronavirus outbreak), trade wars,
political unrest or other events could disrupt our business or operations or those of our manufacturers, regulatory authorities,
or other third parties with whom we conduct business. These events may cause businesses and government agencies to be shut down,
supply chains to be interrupted, slowed, or rendered inoperable, and individuals to become ill, quarantined, or otherwise unable
to work and/or travel due to health reasons or governmental restrictions. For example, Massachusetts recently ordered most businesses
closed, mandating work-from-home arrangements, where feasible, in response to the coronavirus pandemic. These limitations could
negatively affect our business operations and continuity, and could negatively impact our development timelines and ability to
timely perform basic business functions, including making SEC filings and preparing financial reports. If our operations or those
of third parties with whom we have business are impaired or curtailed as a result of these events, the development and commercialization
of our products and product candidates could be impaired or halted, which could have a material adverse impact on our business.
The approach we are taking to discover
and develop novel therapeutics using RNAi may never lead to marketable products.
Our research and development efforts and
our future success is based on our INTASYL™ technology platform. We plan to develop our INTASYL™ products for the treatment
of cancer to be delivered via direct injection for use intratumorally and with ACT by isolating immune cells from patients, treating
the cells ex vivo and then returning them to the patient for treatment. We believe that our INTASYL™ compounds may
offer a new treatment option to current standards of care, such as antibodies, and potentially with a more cost-effective approach.
Successful development of our INTASYL™ compounds by us, or by our collaborative partners, is highly uncertain and depends
on a number of factors, many of which are beyond our control. The scientific research used to support our efforts and approach
to developing RNAi therapeutics is limited. Decisions made by the Company to advance the development of our pipeline, including
those related to our technology or manufacturing processes, may show to be incorrect based on further work by us or our collaborators.
The use of RNAi
is a relatively new scientific discovery and the scientific evidence to support the feasibility of developing drugs based on these
discoveries, or INTASYL™, is limited. Therefore, it is difficult to accurately predict challenges we may face with our product
candidates as they move through the discovery, preclinical and clinical development stages. We may spend large amounts of money
trying to develop our INTASYL™ technology and may never succeed in doing so. In addition, our research methodology by be
unsuccessful in identifying product candidates and results from preclinical and clinical studies may not predict the results that
will be obtained in later phase trials of our product candidates or our product candidates may interact with patients in unforeseen
or harmful ways that may make it impractical to manufacture, market or receive regulatory approval. If we are not successful in
bringing an INTASYL™ product candidate to market, it could negatively impact our business and financial condition and we
may not be able to identify and successfully implement an alternative product development strategy.
A number of different factors could
prevent us from advancing into clinical development, obtaining regulatory approval, and ultimately commercializing our product
candidates on a timely basis, or at all.
Before obtaining regulatory approval for
the sale of any drug candidate, we must conduct extensive preclinical tests and successful clinical trials to demonstrate the safety
and efficacy of our product candidates in humans. Before human clinical trials may commence, we must submit to the FDA an IND application.
An IND application involves the completion of preclinical studies and the submission of the results, together with proposed clinical
protocols, manufacturing information, analytical data and other data in the IND submission. The FDA may require us to complete
additional preclinical studies or disagree with our clinical trial study design. Also, animal models may not exist for some of
the disease areas we choose to develop our INTASYL™ product candidates for. As a result, our clinical trials may be delayed
or we may be required to incur more expense than we anticipated.
Clinical trials require the review and oversight
of IRBs, which approve and continually review clinical investigations and protect the rights and welfare of human subjects. Before
our clinical trials can begin, we must also submit to the FDA a clinical protocol accompanied by the approval of the IRB at the
institution(s) participating in the clinical trial. An inability or delay in obtaining IRB approval could prevent or delay the
initiation and completion of our clinical trials, and the FDA may decide not to consider any data or information derived from a
clinical investigation not subject to initial and continuing IRB review and approval.
Clinical trials of a new drug candidate
require the enrollment of a sufficient number of subjects, including subjects who are suffering from the disease or condition the
drug candidate is intended to treat and who meet other eligibility criteria. Rates of subject enrollment are affected by many factors,
and delays in subject enrollment can result in increased costs and longer development times.
Clinical testing is lengthy and expensive,
and its outcome is highly uncertain. Historical failure rates are high due to number of factors, such as safety and efficacy of
drug candidates. We, our collaborators, the FDA, or an IRB may suspend clinical trials of a drug candidate at any time for various
reasons, including if we or they believe the subjects participating in such trials are being exposed to unacceptable health risks.
Among other reasons, adverse side effects of a drug candidate on subjects in a clinical trial could result in the FDA or other
regulatory authorities suspending or terminating the trial and refusing to approve a particular drug candidate for any or all indications
of use.
An additional number of factors could affect
the timing, cost or outcome of our drug development efforts, including the following:
|
·
|
Delays in filing or acceptance of initial drug applications for our product candidates;
|
|
·
|
Difficulty in securing centers to conduct clinical trials;
|
|
·
|
Conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;
|
|
·
|
Problems in engaging IRBs to oversee trials or problems in obtaining or maintaining IRB approval of studies;
|
|
·
|
Difficulty in enrolling subjects in conformity with required protocols or projected timelines;
|
|
·
|
Third-party contractors failing to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner;
|
|
·
|
Our drug candidates having unexpected and different chemical and pharmacological properties in humans than in laboratory testing and interacting with human biological systems in unforeseen, ineffective or harmful ways;
|
|
·
|
The need to suspend or terminate clinical trials if the participants are being exposed to unacceptable health risks;
|
|
·
|
Insufficient or inadequate supply or quality of our drug candidates or other necessary materials necessary to conduct our clinical trials;
|
|
·
|
Effects of our drug candidates not having the desired effects or including undesirable side effects or the drug candidates having other unexpected characteristics;
|
|
·
|
The cost of our clinical trials being greater than we anticipate;
|
|
·
|
Negative or inconclusive results from our clinical trials or the clinical trials of others for similar drug candidates or inability to generate statistically significant data confirming the efficacy of the product being tested;
|
|
·
|
Changes in the FDA’s requirements for testing during the course of that testing;
|
|
·
|
The impact from the recent coronavirus outbreak;
|
|
·
|
Reallocation of our limited financial and other resources to other clinical programs; and
|
|
·
|
Adverse results obtained by other companies developing similar drugs.
|
A failure of any preclinical study or clinical
trial can occur at any stage of testing. The results of preclinical and initial clinical testing of these products may not necessarily
indicate the results that will be obtained from later or more extensive testing. Preliminary observations made in early stages
of clinical trials with small numbers of subjects are inherently uncertain and initial clinical trial results are not necessarily
indicative of results that will be obtained when full data sets are analyzed or in subsequent clinical trials. Because of these
factors, it is difficult to predict the time and cost of the development of our product candidates. Any delay or failure in obtaining
required approvals may prevent us from completing our preclinical or clinical studies and could have a material adverse effect
on our ability to initiate or commercialize any drug candidate on a timely basis, or at all.
We also are subject to numerous foreign
regulatory requirements governing the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party
reimbursement. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above,
as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Approval by the FDA does not assure
approval by regulatory authorities outside of the United States.
We are dependent on the success of
our product candidates and even if we complete the necessary preclinical and clinical studies, we may not receive or be delayed
in receiving regulatory approval and as a result, we will not be able to commercialize or will be delayed in commercializing our
product candidates.
We have no commercial products and currently
generate no revenue from product sales and may never be able to develop marketable products. The FDA or similar foreign governmental
agencies must approve our products in development before they can be marketed. We, and any of our collaborators, must demonstrate
and establish our product candidate’s safety, purity and effectiveness to patients through extensive clinical trials before
we can submit an NDA or BLA to the FDA for approval. Even if we complete the necessary preclinical and clinical studies, it is
possible that none of the product candidates that we may attempt to develop will obtain the appropriate regulatory approvals needed
to begin selling them or they may be subject to limitations on the indicated uses for which we may market the product.
The process for obtaining FDA and other
approval is both time consuming and costly, with no certainty of a successful outcome, and can often take years following the commencement
of clinical trials, depending on the complexity of the drug candidate. Any analysis we perform of data from clinical activities
is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval.
The FDA has substantial discretion in the approval process and may deny our application, may decide our data is insufficient or
require additional information from us regarding our current or planned clinical trials at any time, and such information may be
costly to provide or cause potentially significant delays in development. Any changes in marketing approval policies or regulatory
statutes and regulations during product development, trials and the review process, may cause delays in the approval of an application.
There is no assurance that we will be able to successfully develop any of our product candidates, and we may spend large amounts
of money trying to resolve these issues and may never succeed in doing so.
We have no experience in filing the applications
necessary to obtain marketing approval and expect that we and need to rely on CROs and regulatory consultants to assist us with
this process. Regulatory approval also requires the submission about the product manufacturing process and inspection of the manufacturing
facilities, to the relevant regulatory authority. Any product candidates we develop may not be effective, may prove to have undesirable
or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or
limit commercial use.
If we experience delays or fail to obtain
marketing approval for any of our product candidates that we may develop, we would be prevented from being able to commercialize
our product candidates and our commercial prospects and ability to generate revenues may be materially impaired.
The FDA could impose a unique regulatory
regime for our therapeutics.
The compounds we intend to develop may represent
a new class of drug, and even though the first RNAi therapeutic was approved in August 2018, the FDA has not yet established any
definitive policies, practices or guidelines in relation to these drugs. While we expect any product candidates that we develop
will be regulated as a new drug under the Federal Food, Drug, and Cosmetic Act, the FDA could decide to regulate them or other
products we may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder
or slow review by the FDA of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining
requirements that we may not have anticipated.
Even if we receive regulatory approval
to market our product candidates, our product candidates may not be accepted commercially, which may prevent us from becoming profitable.
Even if we receive regulatory approval for
a product candidate, we may not generate or sustain revenues from sales of the product. The product candidates that we are developing
are based on new technologies and therapeutic approaches, which are largely unproven. Additionally, RNAi products do not readily
cross the so-called blood brain barrier, are rapidly eliminated from circulating blood and, for various applications, are likely
to require injection or implantation, which will make them less convenient to administer than drugs administered orally. Key participants
in the pharmaceutical marketplace, such as physicians, medical professionals working in large reference laboratories, public health
laboratories and hospitals, third-party payors and consumers may not accept products intended to improve therapeutic results based
on our technologies. For example, RNAi products may be more expensive to manufacture than traditional small molecule drugs, which
may make them costlier than competing small molecule drugs. As a result, it may be more difficult for us to convince the medical
community and third-party payors to accept and use our products or to provide favorable reimbursement. If medical professionals
working with large reference laboratories, public health laboratories and hospitals choose not to adopt and use our technologies,
our products may not achieve broader market acceptance.
Additionally, although we expect that we
will have intellectual property protection for our technology, certain governments may elect to deny patent protection for drugs
targeting diseases with high unmet medical need (e.g., as in the case of HIV) and allow in their country internationally unauthorized
generic competition. If this were to happen, our commercial prospects for developing any such drugs would be substantially diminished
in these countries.
We are dependent on technologies we
license, and if we lose the right to license such technologies or fail to license new technologies in the future, our ability to
develop new products would be harmed.
Many patents in the fields we are pursuing
have already been exclusively licensed to third parties, including our competitors. If any of our existing licenses are terminated,
the development of the products contemplated by the licenses could be delayed or terminated and we may not be able to negotiate
additional licenses on acceptable terms, if at all, which would have a material adverse effect on our business.
We may be unable to protect our intellectual
property rights licensed from other parties; our intellectual property rights may be inadequate to prevent third parties from using
our technologies or developing competing products; and we may need to license additional intellectual property from others.
Therapeutic applications of gene silencing
technologies, formulations, delivery methods and other technologies that we license from third parties are claimed in a number
of pending patent applications, but there is no assurance that these applications will result in any issued patents or that those
patents would withstand possible legal challenges or protect our technologies from competition. The United States Patent and Trademark
Office and patent granting authorities in other countries have upheld stringent standards for the RNAi patents that have been prosecuted
so far. Consequently, pending patents that we have licensed and those that we own may continue to experience long and difficult
prosecution challenges and may ultimately issue with much narrower claims than those in the pending applications. Third parties
may hold or seek to obtain additional patents that could make it more difficult or impossible for us to develop products based
on our technologies without obtaining a license to such patents, which licenses may not be available on attractive terms, or at
all.
In addition, others may challenge the patents
or patent applications that we currently license or may license in the future or that we own and, as a result, these patents could
be narrowed, invalidated or rendered unenforceable, which would negatively affect our ability to exclude others from using the
technologies described in these patents. There is no assurance that these patent or other pending applications or issued patents
we license or that we own will withstand possible legal challenges. Moreover, the laws of some foreign countries may not protect
our proprietary rights to the same extent as do the laws of the United States. Any patents issued to us or our licensors may not
provide us with any competitive advantages, and there is no assurance that the patents of others will not have an adverse effect
on our ability to do business or to continue to use our technologies freely. Our efforts to enforce and maintain our intellectual
property rights may not be successful and may result in substantial costs and diversion of management time. Even if our rights
are valid, enforceable and broad in scope, competitors may develop products based on technology that is not covered by our licenses
or patents or patent applications that we own.
There is no guarantee that future licenses
will be available from third parties for our product candidates on timely or satisfactory terms, or at all. To the extent that
we are required and are able to obtain multiple licenses from third parties to develop or commercialize a product candidate, the
aggregate licensing fees and milestones and royalty payments made to these parties may materially reduce our economic returns or
even cause us to abandon development or commercialization of a product candidate.
Our success depends upon our ability to
obtain and maintain intellectual property protection for our products and technologies.
The applications based on RNAi technologies
claim many different methods, compositions and processes relating to the discovery, development, delivery and commercialization
of RNAi therapeutics. Because this field is so new, very few of these patent applications have been fully processed by government
patent offices around the world, and there is a great deal of uncertainty about which patents will issue, when, to whom and with
what claims. Although we are not aware of any blocking patents or other proprietary rights, it is likely that there will be significant
litigation and other proceedings, such as interference and opposition proceedings in various patent offices, relating to patent
rights in the RNAi field. It is possible that we may become a party to such proceedings.
We are subject to significant competition
and may not be able to compete successfully.
The biotechnology and pharmaceutical industries,
including immuno-oncology, have intense competition and contain a high degree of risk. We face a number of competitors that have
substantially greater experience and greater research and development capabilities, staffing, financial, manufacturing, marketing,
technical and other resources than us, and we may not be able to successfully compete with them. These companies include large
and small pharmaceutical and biotechnology companies, academic institutions, government agencies and other private and public research
organizations.
In addition, even if we are successful in
developing our product candidates, in order to compete successfully we may need to be first to market or to demonstrate that our
products are superior to therapies based on different technologies. Some of our competitors may develop and commercialize products
that are introduced to market earlier than our product candidates or on a more cost-effective basis. A number of our competitors
have already commenced clinical testing of product candidates and may be more advanced than we are in the process of developing
products. If we are not first to market or are unable to demonstrate superiority, on a cost-effective basis or otherwise, any products
for which we are able to obtain approval may not be successful.
Our competitors also compete with us in
acquiring technologies complementary to our INTASYL™ technology. We may face competition with respect to product efficacy
and safety, ease of use and adaptability to modes of administration, acceptance by physicians, timing and scope of regulatory approvals,
reimbursement coverage, price and patent position, including dominant patent positions of others. If we are not able to successfully
obtain regulatory approval or commercialize our product candidates, we may not be able to establish market share and generate revenues
from our technology.
We are subject to potential liabilities
from clinical testing and future product liability claims.
If any of our future products are alleged
to be defective, they may expose us to claims for personal injury by subjects in clinical trials of our products. If our products
are approved by the FDA, users may claim that such products caused unintended adverse effects. We will seek to obtain clinical
trial insurance for clinical trials that we conduct, as well as liability insurance for any products that we market. There is no
assurance that we will be able to obtain insurance in the amounts we seek, or at all. We anticipate that licensees who develop
our products will carry liability insurance covering the clinical testing and marketing of those products. There is no assurance,
however, that any insurance maintained by us or our licensees will prove adequate in the event of a claim against us. Even if claims
asserted against us are unsuccessful, they may divert management’s attention from our operations and we may have to incur
substantial costs to defend such claims.
Any drugs we develop may become subject
to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which could have a material
adverse effect on our business.
If approved, we intend to sell our products
primarily to hospitals, oncologists and clinics, which receive reimbursement for the healthcare services they provide to their
patients from third-party payors, such as Medicare, Medicaid and other domestic and international government programs, private
insurance plans and managed care programs. Most third-party payors may deny reimbursement if they determine that a medical product
was not used in accordance with cost-effective treatment methods, as determined by the third-party payor, was used for an unapproved
indication or if they believe the cost of the product outweighs its benefits. Third-party payors also may refuse to reimburse for
experimental procedures and devices. Furthermore, because our programs are still in development, we are unable at this time to
determine their cost-effectiveness and the level or method of reimbursement for them. Increasingly, the third-party payors who
reimburse patients are requiring that drug companies provide them with predetermined discounts from list prices and are challenging
the prices charged for medical products. If the price we are able to charge for any products we develop is inadequate in light
of our development and other costs, our profitability could be adversely affected.
We currently expect that any drugs we develop
may need to be administered under the supervision of a physician. Under currently applicable law, drugs that are not usually self-administered
may be eligible for coverage by the Medicare program if:
|
·
|
They are “incidental” to a physician’s services;
|
|
·
|
They are “reasonable and necessary” for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standards of medical practice;
|
|
·
|
They are not excluded as immunizations; and
|
|
·
|
They have been approved by the FDA.
|
Insurers may refuse to provide insurance
coverage for newly approved drugs, including drugs in our clinical pipeline, or insurance coverage may be delayed or be more limited
than the purpose for which the drugs are approved by the FDA. Moreover, eligibility for insurance coverage does not imply that
any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale
and distribution costs. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not
be made permanent. Reimbursement may be based on payments for other services and may reflect budgetary constraints or imperfections
in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs
or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be
sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Our inability to promptly obtain coverage and profitable reimbursement rates from both
government-funded and private payors for new drugs that we develop could have a material adverse effect on our operating results,
our ability to raise capital needed to develop products and our overall financial condition.
Additionally, third-party payors are increasingly
attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products and services.
Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party
payors may adversely affect the demand for and price levels of our products. If our customers are not reimbursed for our products,
they may reduce or discontinue purchases of our products, which could have a material adverse effect on our business, financial
condition and results of operations.
Comprehensive healthcare reform legislation,
which became law in 2010, and any revisions to this legislation, could adversely affect our business and financial condition. Among
other provisions, the legislation provides that a “biosimilar” product may be approved by the FDA on the basis of analytical
tests and certain clinical studies demonstrating that such product is highly similar to an existing, approved product and that
switching between an existing product and the biosimilar product will not result in diminished safety or efficacy. This abbreviated
regulatory approval process may result in increased competition if we are able to bring a product to market. The legislation also
includes more stringent compliance programs for companies in various sectors of the life sciences industry with which we may need
to comply and enhanced penalties for non-compliance with the new healthcare regulations. Complying with new regulations may divert
management resources, and inadvertent failure to comply with new regulations may result in penalties being imposed on us.
Some states and localities have established
drug importation programs for their citizens, and federal drug import legislation has been introduced in Congress. The Medicare
Prescription Drug Plan legislation, which became law in 2003, required the Secretary of Health and Human Services to promulgate
regulations for drug reimportation from Canada into the United States under some circumstances, including when the drugs are sold
at a lower price than in the United States. The Secretary, however, retained the discretion not to implement a drug reimportation
plan, if the Secretary finds that the benefits do not outweigh the costs, and has so far declined to approve a reimportation plan.
Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances.
Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products
that we may develop and adversely affect our future revenues and prospects for profitability.
With the current U.S. administration and
Congress, there may be additional legislative changes, including repeal and replacement of certain provisions of the Affordable
Care Act. It remains to be seen, however, precisely what new legislation will provide, when it will be enacted and what impact
it will have on the availability of healthcare and containing or lowering the cost of healthcare. Such reforms could have an adverse
effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval
and may affect our overall financial condition and ability to develop product candidates.
Even if we obtain regulatory approvals,
our marketed drugs will be subject to ongoing regulatory review. If we fail to comply with continuing U.S. and foreign regulations,
we could lose our approvals to market drugs and our business would be materially and adversely affected.
Following regulatory approval of any drugs
we may develop, we will remain subject to continuing regulatory review, including the review of adverse drug experiences and clinical
results that are reported after our drug products are made available to patients. This would include results from any post-marketing
tests or vigilance required as a condition of approval. The manufacturer and manufacturing facilities we use to make any of our
drug products will also be subject to periodic review and inspection by the FDA. The discovery of any new or previously unknown
problems with the product, manufacturer or facility may result in restrictions on the drug or manufacturer or facility, including
withdrawal of the drug from the market. We would continue to be subject to the FDA requirements governing the labeling, packaging,
storage, advertising, promotion, recordkeeping and submission of safety and other post-market information for all of our product
candidates, even those that the FDA had approved. If we fail to comply with applicable continuing regulatory requirements, we may
be subject to fines, suspension or withdrawal of regulatory approval, product recalls and seizures, operating restrictions and
other adverse consequences.
If we fail to attract, hire and retain
qualified personnel, we may not be able to design, develop, market or sell our products or successfully manage our business.
Our business prospects are dependent on
the principal members of our executive team, the loss of whose services could make it difficult for us to manage our business successfully
and achieve our business objectives. While we have entered into employment agreements with each of our executive officers, they
could leave at any time, in addition to our other employees, who are all “at will” employees. Our ability to identify,
attract, retain and integrate additional qualified key personnel is also critical to our success. Competition for skilled research,
product development, regulatory and technical personnel is intense, and we may not be able to recruit and retain the personnel
we need. The loss of the services of any key research, product development, regulatory and technical personnel, or our inability
to hire new personnel with the requisite skills, could restrict our ability to develop our product candidates.
Risks Relating to Our Financial Condition
We may not be able to obtain sufficient
financing and may not be able to develop our product candidates.
We
believe that our existing cash at December 31, 2019, and the proceeds received from our capital raises completed in February 2020,
will be sufficient to fund our currently planned operations for at least the next 12 months from the date this Annual Report on
Form 10-K is filed. However, we have generated significant losses to date, have not generated any product revenue and may
not generate product revenue in the foreseeable future, or ever. We expect to incur significant operating losses as we advance
our product candidates through drug development and the regulatory process. In the future, we may need to issue equity or incur
debt in order to fund our planned expenditures, as well as to make acquisitions and other investments. We cannot assure you that
equity or debt financing will be available to us on acceptable terms, or at all. If we cannot, or are limited in the ability to,
issue equity, incur debt or enter into strategic collaborations, we may be unable to fund the discovery and development of our
product candidates, address gaps in our product offerings or improve our technology.
We anticipate that we will need to raise
substantial amounts of money to fund a variety of future activities integral to the development of our business, which may include
but is not limited to the following:
|
·
|
To conduct research and development to successfully develop our technologies;
|
|
·
|
To obtain regulatory approval for our products;
|
|
·
|
To file and prosecute patent applications and to defend and assess patents to protect our technologies;
|
|
·
|
To retain qualified employees, particularly in light of intense competition for qualified personnel;
|
|
·
|
To manufacture products ourselves or through third parties;
|
|
·
|
To market our products, either through building our own sales and distribution capabilities or relying on third parties; and
|
|
·
|
To acquire new technologies, licenses or products.
|
Moreover, the global coronavirus pandemic
has led to significant uncertainty and increased volatility in the capital markets. If these conditions in the capital markets
continue for an extended period of time it may impact our ability to raise capital. If
we fail to obtain additional funding when needed, we may ultimately be unable to continue to develop and potentially commercialize
our product candidates, and we may be forced to scale back or terminate our operations or seek to merge with or be acquired by
another company.
Future financing may be obtained through,
and future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our stockholders
or may otherwise adversely affect our business.
If we raise funds through the issuance of
debt or equity, any debt securities or preferred stock issued will have rights, preferences and privileges senior to those of holders
of our common stock in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled,
there may be no assets remaining to pay out to the holders of common stock. In addition, if we raise funds through the issuance
of additional equity, whether through private placements or public offerings, such an issuance would dilute current stockholders’
ownership in us.
The terms of debt securities may also impose
restrictions on our operations, which may include limiting our ability to incur additional indebtedness, to pay dividends on or
repurchase our capital stock, or to make certain acquisitions or investments. In addition, we may be subject to covenants requiring
us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of
our control.
We expect to continue to incur significant
research and development expenses, which may make it difficult for us to attain profitability, and may lead to uncertainty as to
our ability to continue as a going concern.
We expend substantial funds to develop our
technologies, and additional substantial funds will be required for further research and development, including preclinical testing
and clinical trials of any product candidates, and to manufacture and market any products that are approved for commercial sale.
Because the successful development of our products is uncertain, we are unable to precisely estimate the actual funds we will require
to develop and potentially commercialize them. In addition, we may not be able to generate enough revenue, even if we are able
to commercialize any of our product candidates, to become profitable.
If we are unable to achieve or sustain profitability
or to secure additional financing, we may not be able to meet our obligations as they come due, raising substantial doubts as to
our ability to continue as a going concern. Any such inability to continue as a going concern may result in our common stockholders
losing their entire investment. There is no guarantee that we will become profitable or secure additional financing. Our financial
statements do not include any adjustments to, or classification of, recorded asset amounts and classification of liabilities that
might be necessary if we were unable to continue as a going concern. Changes in our operating plans, our existing and anticipated
working capital needs, the acceleration or modification of our expansion plans, increased expenses, potential acquisitions or other
events will all affect our ability to continue as a going concern.
Risks Relating to Our Securities
The price of our common stock has
been and may continue to be volatile.
The stock markets, in general, and
the markets for drug delivery and pharmaceutical company stocks, in particular, have experienced extreme volatility, particularly
in response to the coronavirus outbreak, that has often been unrelated to the operating performance of particular companies. These
broad market fluctuations may adversely affect the trading price of our common stock. In addition, the limited trading volume
of our stock may contribute to its volatility.
In the past, following periods of volatility
in the market price of a particular company’s securities, litigation has often been brought against that company. If litigation
of this type is brought against us, it could be extremely expensive and divert management’s attention and the Company’s
resources.
We have issued preferred stock in
the past and possibly may issue more preferred stock in the future, and the terms of the preferred stock may reduce the value of
our common stock.
We are authorized to issue up to 10,000,000
shares of preferred stock in one or more series. Our Board of Directors may determine the terms of future preferred stock offerings
without further action by our stockholders. The issuance of our preferred stock could affect the rights of existing stockholders
or reduce the value of our outstanding preferred stock or common stock. In particular, rights granted to holders of certain series
of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights and
restrictions on our ability to merge with or sell our assets to a third party.
We may acquire other businesses or
form joint ventures that may be unsuccessful and could dilute your ownership interest in the Company.
As part of our business strategy, we may
pursue future acquisitions of other complementary businesses and technology licensing arrangements. We also may pursue strategic
alliances. We have limited experience with respect to acquiring other companies and with respect to the formation of collaborations,
strategic alliances and joint ventures. We may not be able to integrate such acquisitions successfully into our existing business,
and we could assume unknown or contingent liabilities. We also could experience adverse effects on our reported results of operations
from acquisition related charges, amortization of acquired technology and other intangibles and impairment charges relating to
write-offs of goodwill and other intangible assets from time to time following the acquisition. Integration of an acquired company
requires management resources that otherwise would be available for ongoing development of our existing business. We may not realize
the anticipated benefits of any acquisition, technology license or strategic alliance. There is no assurance that we will be successful
in developing such assets, and a failure to successfully develop such assets could diminish our prospects.
To finance future acquisitions, we may choose
to issue shares of our common stock or preferred stock as consideration, which would dilute current stockholders’ ownership
interest in us. Alternatively, it may be necessary for us to raise additional funds through public or private financings. Additional
funds may not be available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our
stockholders. Any future acquisitions by us also could result in large and immediate write-offs, the incurrence of contingent liabilities
or amortization of expenses related to acquired intangible assets, any of which could harm our operating results.
We do not anticipate paying cash dividends
in the foreseeable future.
Our business requires significant funding.
We currently plan to invest all available funds and future earnings in the development and growth of our business and do not anticipate
paying any cash dividends on our common stock in the foreseeable future. As a result, capital appreciation, if any, of our common
stock will be the sole source of potential gain for our stockholders for the foreseeable future.
Provisions of our certificate of incorporation
and bylaws and Delaware law might discourage, delay or prevent a change of control of the Company or changes in our management
and, as a result, depress the trading price of our common stock.
Our certificate of incorporation and bylaws
contain provisions that could discourage, delay or prevent a change of control of the Company or changes in our management that
the stockholders of the Company may deem advantageous. These provisions:
|
·
|
Authorize the issuance of “blank check” preferred stock that our Board of Directors could issue to increase the number of outstanding shares and to discourage a takeover attempt;
|
|
·
|
Prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;
|
|
·
|
Provide that the Board of Directors is expressly authorized to adopt, alter or repeal our bylaws; and
|
|
·
|
Establish advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted upon by stockholders at stockholder meetings.
|
Although we believe these provisions collectively
provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board of Directors, they
would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or
prevent any attempts by our stockholders to replace or remove our current management team by making it more difficult for stockholders
to replace members of our Board of Directors, which is responsible for appointing the members of our management.
Moreover, because we are incorporated in
Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person
who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the
date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination
is approved in a prescribed manner.